Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements

12.08.2022 - Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate ...

Related Keywords

Canada ,Ottawa ,Ontario , ,Taro Pharmaceutical Industries Stock ,Canada Vigilance Program ,Health Canada ,Zoledronic Acid Injection ,Taro Zoledronic Acid Injection ,Medication Information ,Canada Vigilance Reporting Form ,Canada Vigilance ,Postal Locator ,Canada Vigilance Reporting Forms ,Medeffect Canada Web ,Taro Pharmaceutical Industries ,